SCHEMBL3539439

SCHEMBL3539439

Cc1ccc(-c2nc(C(=O)N3CCCC4CCCC=C43)cs2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.48
RAB9A P51151 2/20 0.46
NPC1 O15118 1/20 0.46
POLB P06746 1/20 0.46
TLR7 Q9NYK1 1/20 0.40
TRPC3 Q13507 5/20 0.40
TRPC6 Q9Y210 5/20 0.40
TRPA1 O75762 1/20 0.40
CACNA1C Q13936 1/20 0.40
SCN5A Q14524 1/20 0.40
TRPV1 Q8NER1 1/20 0.40
TRPV4 Q9HBA0 1/20 0.40
ACKR3 P25106 1/20 0.39
KDM4E B2RXH2 2/20 0.38
CLK1 P49759 1/20 0.38
KMT2A Q03164 1/20 0.38
RXFP1 Q9HBX9 1/20 0.38
NTMT1 Q9BV86 1/20 0.36
CNR1 P21554 1/20 0.36
CNR2 P34972 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3537642 0.91 ACKR3 (0.38) ALDH1A1RAB9ANPC1POLBACKR3
SCHEMBL3537684 0.90 KDM4E (0.44) ALDH1A1RAB9ANPC1POLBTLR7
SCHEMBL3542690 0.90 RAB9A (0.45) ALDH1A1RAB9ANPC1TLR7TRPC3
SCHEMBL3545134 0.90 ACKR3 (0.46) TLR7ACKR3CNR1CNR2PIN1
SCHEMBL3535648 0.89 ACKR3 (0.47) TLR7ACKR3CNR1CNR2PIN1
SCHEMBL5661785 0.89 ACKR3 (0.38) ALDH1A1RAB9ANPC1POLBTLR7
SCHEMBL3540045 0.87 KDM4E (0.39) ALDH1A1RAB9AACKR3KDM4ECLK1
SCHEMBL27751094 0.87 TLR7 (0.43) ALDH1A1POLBTLR7ACKR3KDM4E
SCHEMBL4983913 0.87 ACKR3 (0.45) ALDH1A1ACKR3CNR1CNR2PIN1
SCHEMBL3538100 0.86 KDM4E (0.38) ALDH1A1RAB9ANPC1ACKR3KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7645773-B2 Thiazoles as inhibitors of 11β-hydroxysteroid dehydrogenase HOFFMANN-LA ROCHE INC. (US) 2010-01-12 US disclosed
US-20070167622-A1 [2-(3-chloro-phenyl)-thiazol-4-yl]-(octahydro-quinolin-1-yl)-methanone; azocan-1-yl-[2-(2,3-dichloro-phenyl)-thiazol-4-yl]-methanone; type II diabetes mellitus and metabolic syndrome GILLESPIE PAUL 2007-07-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070167622-A1 [2-(3-chloro-phenyl)-thiazol-4-yl]-(octahydro-quinolin-1-yl)-methanone; azocan-1-yl-[2-(2,3-dichloro-phenyl)-thiazol-4-yl]-methanone; type II diabetes mellitus and metabolic syndrome GOT2, PC, CYP11B2 ALDH1A1 707/4885RAB9A 3912/4885NPC1 891/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.